Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview.

Telci Caklili, Ozge; Cesur, Mustafa; Mikhailidis, Dimitri P; Rizzo, Manfredi.

Afiliação

Telci Caklili O; Department of Endocrinology and Metabolism, Faculty of Medicine, University of Istanbul, Istanbul, Türkiye.
Cesur M; Department of Endocrinology and Metabolism, Ankara Guven University Hospital, Ankara, Türkiye.
Mikhailidis DP; Department of Clinical Biochemistry and Department of Surgical Biotechnology, Division of Surgery and Interventional Science, Medical School, University College London (UCL), London, UK.
Rizzo M; School of Medicine, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), University of Palermo, Palermo, Italy.

Diabetes Metab Syndr Obes ; 16: 1767-1774, 2023.

Article em En | MEDLINE | ID: mdl-37337548

ABSTRACT

Obesity has become an epidemic and a worldwide problem and its treatment is ever-evolving. Apart from diet and exercise, medication and surgery are other options. After disappointing side effects of various obesity drugs, new treatments showed promising results. This review discusses the following anti-obesity drugs liraglutide, semaglutide, tirzepatide, orlistat, as well as the phentermine/topiramate and bupropion/naltrexone combinations. These drugs have been approved by the Food and Drug Administration (FDA) for weight reduction except for tirzepatide which is still under evaluation. Efficacy and tolerable safety profiles of some of these drugs contribute to the management of obesity and reduce the complications associated with this chronic disease.

Palavras-chave

bupropion/naltrexone; drugs; liraglutide; obesity; orlistat; phentermine/topiramate; semaglutide; tirzepatide

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article